Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
173 hedge funds and large institutions have $1.25B invested in Dicerna Pharmaceuticals, Inc. in 2021 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 64 increasing their positions, 58 reducing their positions, and 57 closing their positions.
237% more call options, than puts
Call options by funds: $15.1M | Put options by funds: $4.49M
10% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 58
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
15% less funds holding
Funds holding: 203 → 173 (-30)
44% less capital invested
Capital invested by funds: $2.22B → $1.25B (-$973M)
51% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 57
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$35.8M |
| 2 |
CC
Commodore Capital
New York
|
+$35.7M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$34.5M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$22.1M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$21.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$76.4M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$58.2M |
| 3 |
PA
Perceptive Advisors
New York
|
-$29.9M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$18.5M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
-$16.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TWA
226
TCI Wealth Advisors
Tucson,
Arizona
| – | -$6K | -168 | Closed |
|
|
SFP
227
Sterling Financial Planning
Sparta,
New Jersey
| – | -$4K | -100 | Closed |
|
|
IFAM
228
Institutional & Family Asset Management
Fort Collins,
Colorado
| – | -$966 | -35 | -69% |
|
229
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$1K | -30 | Closed |
|
DRNA Hedge Fund Activity: Q3 2021 in Review
173 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q3 2021, worth a combined $1.25B — down 44% from $2.22B a quarter earlier.
Sellers outnumbered buyers: 57 funds closed out of DRNA and 28 opened new positions — a net loss of 29 holders — while 58 trimmed existing stakes and 64 added.
The largest buyer was State Street, adding an estimated $35.8M. The largest seller was Wellington Management Group, cutting an estimated $76.4M.
- 173 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q3 2021, down from 203 in Q2 2021.
- Funds reported $1.25B of Dicerna Pharmaceuticals, Inc. stock for Q3 2021, down 44% quarter-over-quarter.
- 28 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q3 2021 and 57 closed out, a net change of -29 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q3 2021 was State Street, an estimated $35.8M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q3 2021 was Wellington Management Group, an estimated $76.4M sold.
Based on aggregated 13F filings for Q3 2021.